20212020201920182017201620152014 March 03, 2021 Summary ToggleSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 February 25, 2021 Summary ToggleSpero Therapeutics to Present at Investor Conferences in March February 05, 2021 Summary ToggleSpero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial January 29, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 21, 2021 Summary ToggleSpero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr December 17, 2020 Summary ToggleSpero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer December 16, 2020 Summary ToggleSpero Therapeutics Added to the NASDAQ Biotechnology Index December 10, 2020 Summary ToggleSpero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease December 02, 2020 Summary ToggleSpero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer November 30, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
